Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.
Similar stories
1 outlet
Optimising a digitally delivered behavioural weight loss programme: a factorial cluster randomised controlled trial
nature.com
19.09.2026
Related stories
Why the CDC is excluding measles deaths in Pennsylvania even as outbreak appears to be ‘accelerating’
Sisters with life-limiting condition taking NHS fight to Parliament
Abortion is on the ballot again as post-Roe policies continue to evolve
Your smartwatch isn't accurately counting how many calories you burn, study says
Scientists reveal why Kent meningitis outbreak was so deadly
Scientists discover why Kent meningitis outbreak was so severe